FDA changes prescribing information for new Alzheimer's drug
Following weeks of criticism of the FDA decision to approve Biogen's Alzheimer's drug Aduhelm, experts within the health authority are narrowing the range of patients that the medicine is recommended for.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Just one month after the US Food and Drug Administration (FDA) vouched for Biogen's drug Aduhelm for treating Alzheimer's disease, the authority has adjusted the prescribing information for this medication, which changes the patients that the drug should be recommended to.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
